Simvastatin Down Regulates mRNA Expression of RANTES and CCR5 in Posttransplant Renal Recipients With Hyperlipidemia

Transplantation Proceedings

Volumn 38, Issue 9, 2006, Pages 2899-2904

  Li, Q ^a   Wang, D ^b   Wang, Y ^a   Xu, Q ^c  

^a Second Hospital of Xiamen   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; LIPID; MESSENGER RNA; RANTES; SIMVASTATIN;

ADULT; ANALYTIC METHOD; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HYPERLIPIDEMIA; KIDNEY GRAFT; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECIPIENT;

ADULT; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIPIDS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RANTES; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIMVASTATIN;

EID: 33751082398     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.08.136     Document Type: Article

References (26)

1. Nankivell B.J., Borrows R.J., Chir M.B., et al. The natural history of chronic allograft nephropathy. N Engl J Med 349 (2003) 2326
2. Van der Woude F.J., and Hollander A.A.M.J. Rejection after kidney transplantation: New concepts, new therapeutic options. Transplant Proc 30 (1998) 2419
3. Aguirrezabalaga J., Fernandez-Selles C., Otero A., et al. Lipid profiles in liver transplantation in patients receiving tacrolimus or cyclosporin. Transplant Proc 33 (2001) 1064
4. Kisielnicka E., Zdrojewski Z., Wroblewska M., et al. Lipid disturbances in a two-year follow-up after successful kidney transplantation. Transplant Proc 32 (2000) 1358
5. Moench C., Uhrig A., Lohse A.W., et al. Differential diagnosis of cytomegalovirus infection and acute rejection by serum CC-chemokine measurement after orthotopic liver transplantation. Transplant Proc 35 (2003) 2084
6. Almenar Bonet L., Martinez-Dolz L., Arnau Vives M.A., et al. Lipid-lowering effect of atorvastatin in heart transplantation. Transplant Proc 34 (2002) 179
7. Berrebi D., Languepin J., and Ferkdadji L. Cytokines, chemokine receptors, and homing molecule distribution in the rectum and stomach of pediatric patients with ulcerative colitis. J Pediatr Gastroenterol Nutr 37 (2003) 300
8. Anders H.J., Vielhauer V., and Schlondorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int 63 (2003) 401
9. Anders H.J., Frink M., Linde Y., et al. CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J Immunol 170 (2003) 5658
10. Nelson P.J., and Krensky A.M. Chemokines, chemokine receptors, and allograft rejection. Immunity 14 (2001) 377
11. Handel T.M., and Lau E.K. Chemokine structure and receptor interactions. Ernst Schering Res Found Workshop 45 (2004) 101
12. Gibejov A. Chemokine receptors. Acta Univ Palacki Olomuc Fac Med 143 (2000) 9
13. Aguirrezabalaga J., Fernandez-Selles C., Fraguela J., et al. Lipid profiles after liver transplantation in patients receiving tacrolimus or cyclosporin. Transplant Proc 34 (2002) 1551
14. Aakhus S., Dahi K., and Wideroe T.E. Hyperlipidemia in renal transplant patients. J Int Med 239 (1996) 407
15. Hancock W. Chemokines and transplant immonobiology. J Am Soc Nephrol 13 (2002) 821
16. Schwabe R.F., Bataller R., and Brenner D.A. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol 285 (2003) G949
17. Iijima W., Ohtani H., Nakayama T., et al. Infiltrating CD8+ T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules: a potential self-recruiting mechanism. Am J Pathol 163 (2003) 261
18. Wang Y., Li H., Lu Y., et al. Effect of apolipoprotein E gene polymorphism on serum lipid levels before and after renal transplantation. Chinese J Organ Transpant 25 (2004) 294
19. Lopes-Virelia M., Mironina M., Stephen P., et al. Role of Simvastatin as an immunomodulator in type 2 diabetes. Diabetes Care 27 (2004) 908
20. Wenke K., Meiser B., Thiery J., et al. Simvastatin initiated early after heart transplantation 8-year prospective experience. Circulation 107 (2003) 93
21. Chello M., Mastroroberto P., Patti G., et al. Simvastatin attenuates leucocyte-endothelial interactions after coronary revascularisation with cardiopulmonary bypass. Heart 89 (2003) 538
22. Kasiske B.L., O'Donnell M.P., Garvis W.J., et al. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in the rat 5/6 nephrectomy model of chronic renal failure. Circ Res 62 (1988) 367
23. Lee S.K., Jin S.Y., Han D.C., et al. Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats. Nephrol Dial Transplant 8 (1993) 1338
24. Sparrow C.P., Burton C.A., Hernande M., et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 21 (2001) 115
25. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 (1987) 156
26. Greenwood J., Walters C.E., Pryce G., et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 17 (2003) 905